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Abstract
The identification of complex disease susceptibility loci has been accelerated considerably by advances in
high-throughput genotyping technologies, improved insight into correlation patterns of common variants and the
availability of large-scale sample sets. Linkage scans and small-scale candidate gene studies have now given way to
genome-wide association scans. In this review, we summarize insights gained from the past, highlight practical
issues relating to the design and analysis of current state-of-the-art GWA studies and look into future trends in
the field of human complex trait genetics.
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INTRODUCTION
Common complex diseases have traditionally been
ascribed to complicated networks of genetic and
environmental factors. The search for genetic suscep-
tibility loci has been much more straightforward for
Mendelian disorders than for multifactorial traits,
where numerous variants of modest or small effect
sizes contribute to the genetic background of disease.
The common disease–common variant and multiple
rare variant hypotheses had been proposed as distinct
scenarios and polarized the field of complex disease
genetics for some time. However, emerging evi-
dence indicates that the genetic aetiology of complex
traits is likely to be based on a combination of mul-
tiple rare and common susceptibility loci.
The field of human complex trait genetics
has undergone major transformation over the past
decade. Researchers have gradually moved from
family-based approaches for investigating linkage
to association studies offering (and, lately, deliver-
ing) the promise of complex disease locus
robust identification. The journey has witnessed
study design trends come and go, with valuable les-
sons learnt from each such era. Rapid technological
developments, coupled with the availability of larger
sample sizes and a better understanding of human
genome sequence variation, continue to facilitate
progress in the field. In this review, we aim to
distil lessons from the past few years in the field of
complex disease genetics, describe the present state-
of-the-art for finding common susceptibility loci and
look into emerging themes for the near future.
PAST
Genetic association studies have, over the last decade,
evolved from genome-wide linkage scans to candi-
date gene approaches, to gene-centric designs aiming
to capture the majority of common variation and,
ultimately, to genome-wide association (GWA)
scans. Several factors have influenced this trajectory,
including our understanding of human genome
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genotyping technologies (moving from low- to
medium- to high-throughput approaches).
Family-based linkage studies prevailed in the lit-
erature for several years as they constituted the only
means of targeting variation genome-wide at the
time. Linkage studies tended to lead to the identifi-
cation of numerous peaks that were rarely repro-
duced in independent studies. For example, in type
2 diabetes (T2D), although more than 40 linkage
scans have been performed, the overall picture has
been one of multiple modest signals, few of which
show evidence of replication [1, 2]. Linkage signals
typically encompass several megabases of sequence
and the resulting localization resolution is low
[although this improved marginally when single
nucleotide polymorphism (SNP)-based linkage
scans were introduced] [3, 4]. Consortia formed for
the meta-analysis of linkage scans of particular phe-
notypes served to distil the number of statistically
believable linkage peaks [2] and promising signals
were traditionally followed up by fine-mapping
experiments [5]. Very few such endeavours have
led to the identification of causal disease susceptibility
variants [6, 7]. This is perhaps not surprising, as link-
age disequilibrium (LD) mapping efforts under link-
age peaks tended to make use of SNPs with common
minor allele frequencies (MAFs), whereas linkage
signals were more likely to reflect more penetrant
effects of rare variants. Moreover, because of the rel-
atively small number of families and microsatellite
markers used, most of these studies may have been
underpowered to detect many of the effects that
association approaches have thus far discovered.
The field shifted towards association studies,
exemplified over the last decade by the candidate
gene study. Candidate gene studies focused on a
few, if not just a single, variant(s) within a biologi-
cally plausible candidate gene. They were typically
carried out in a few hundreds of disease cases and
controls, or in a few hundreds of nuclear families,
consisting of affected offsprings and unaffected par-
ents. The latter approach (transmission disequilib-
rium test) [8] reached high popularity levels in the
nineties due to its property of being robust to pop-
ulation stratification. Although several notable
exceptions exist (for example [9, 10] from the field
of T2D), candidate gene studies on the whole did
not deliver many robustly replicating disease suscep-
tibility loci. This irreproducibility of results could be
ascribed to a combination of several contributing
factors: low power (as a result of small sample sizes)
to detect what we now recognize as modest or small
effects; limited understanding of disease aetiopatho-
genesis leading to inappropriate selection of candi-
date loci; low thresholds for declaring significance
and over-interpretation of results; and inadequate
capture of variation across the genes of interest.
The International HapMap Project [11] greatly
increased our understanding of correlation patterns
(LD) between common variants across the genome.
This enabled the selection of maximally informative,
non-redundant sets of markers across genes or
regions of interest. A wide variety of haplotype-
based and pairwise tagging methods were developed
[12–15]. Tag SNP studies continue to be carried out;
they employ information from relevant HapMap
populations to select SNPs capturing the majority
of common variation across targeted loci. These
markers are then genotyped and analysed in the data-
sets of interest, and inferences about their proxy
variants are made on the basis of the association
patterns observed.
Advances in high-throughput, high-accuracy
genotyping platforms marked a new era for associa-
tion studies, enabling the concurrent examination of
hundreds of thousands of SNPs. Sufficient power
in GWA studies was facilitated by the availability
of large-scale sample collections. Over the last few
years, GWA scans have succeeded in detecting
and establishing complex trait associations, and
have started to provide valuable insights into disease
aetiopathogenesis.
PRESENT
GWA studies undoubtedly constitute the present
state-of-the-art in efforts to elucidate the genetic
aetiology of complex phenotypes. Several commer-
cial products offering the potential to simultaneously
assay hundreds of thousands of SNPs genome-wide
are available from companies such as Affymetrix
and Illumina. These have varying SNP content and
density, and have been designed using diverse
marker selection strategies (Table 1). For example,
arrays with an exon-centric SNP content, such as
the Illumina Human-1, reflect strategies focusing
on potentially functional variants. LD-based plat-
forms contain tag sets of SNPs selected to maximize
the amount of common variation captured on the
basis of HapMap data. Affymetrix platforms comprise
quasi-randomly distributed SNPs or a combination
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potential role in complex disease susceptibility,
copy number variants (CNVs) are also increasingly
featured.
Table 1 summarizes the extent to which different
platforms capture common (MAF>0.05) variation
based on published evaluations in the three different
HapMap phase II populations [11]. Coverage
in European- and East Asian-descent populations
is very high and has substantially improved with
next generation chips. Information capture in
African-descent populations is lower, reflecting
higher recombination rates and lower levels of
inter-marker correlation. However, it has been
shown theoretically that coverage of all common
variation based on HapMap has been overestimated
and that larger sample sizes and denser marker sets are
required for more accurate estimation of tagging
SNP efficacy [19, 20]. Overestimation of previously
reported coverage estimates has also been empirically
confirmed by the analysis of sequence-derived vari-
ation data from 76 genes in HapMap samples [21].
Although variation capture is an important consider-
ation in GWA study design, it is not the sole deter-
minant of power.
The statistical power of a GWA study to detect
variants associated with disease is a function of sample
size, the susceptibility locus effect magnitude, risk
allele frequency of the queried SNP and its correla-
tion with the causal variant. Although the allelic
architecture of complex traits has not been fully
characterized yet, recent GWA scans and follow-up
studies have highlighted that common susceptibility
loci are likely to have modest or small effect sizes
[allelic odds ratios (ORs) between 1.1 and 1.5].
In a genome-wide setting, the large number of
tests performed requires stringent thresholds
for declaring statistical genome-wide significance
(P¼5 10
 8) [22, 23], necessitating large-scale
sample sizes. For example, in order to achieve 90%
power to detect a risk allele with 0.20 frequency and
an allelic OR of 1.2 (at the genome-wide signifi-
cance level), more than 6000 affected individuals
and twice as many controls would be required
(Figure 1). To achieve the same power to detect
similar effects at lower frequency variants (frequency
of 0.05 or less), a GWA study would need upwards
of 20000 cases (Figure 1).
Along with sample size considerations, GWA
studies have also given rise to several logistical
challenges: for example, issues relating to automated
but accurate genotype calling, programmatic data
handling and parsing, genotype quality control
(QC) standards and analytical considerations that
did not previously apply to smaller scale studies.
Genotype calling is the process by which hybrid-
ization intensities on genome-wide chips are trans-
lated into genotypes. Typically, intensities are
normalized and transformed into coordinates which
yield distinct genotype clouds. As high call rate and
accuracy of genotype calling are important factors in
safe-guarding QC standards in GWA scans, a variety
of genotype calling algorithms have been developed
and continue to evolve [24–27]. The possible adverse
effects of inaccurate genotype calling in downstream
analyses have been recognized for a while [28].
Table 1: Overview of marker content and array design across commercially available platforms and coverage of
common variation (MAF>0 . 0 5 )b a s e do nH a p M a pp h a s eI Id a t a
Platform Number of
markers
Array
design
Coverage
in CEU
a (%)
Coverage in
JPT
b+C H B
c (%)
Coverage
inYRI
d (%)
Source
Illumina Human-1 More than109 000 Gene 26 28 12 [16]
Illumina HumanHap300 317511 Tag 75 63 28 [16]
Affymetrix SNPArray 5.0 500568 Random 65 66 41 [16]
Illumina HumanHap550 555352 Tag 87 83 50 [17]
Illumina Human610 620 901 Tag, CNV
e 89 86 58 [18]
Illumina HumanHap650Y 660917 Tag 87 84 60 [17]
Affymetrix SNPArray 6.0 More than1800000 Random+Tag,CNV
e 83 84 62 [17]
Illumina Human1M 1199187 Tag,CNV
e 93 92 68 [17]
aUtahresidentswith ancestry fromnorthern andwestern Europe.
bJapanese fromTokyo, Japan.
cHan Chinese from Beijing,China.
dYoruba from Ibadan,Nigeria.
eCopy number variation.
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ing association signals is an essential aspect of geno-
type QC.
Genotype QC is an extremely important step in
GWA studies, as it can dramatically reduce the
number of false positive associations. The field has
converged to an essential set of QC checks; Figure 2
summarizes the sample- and SNP-based QC steps
that are typically employed.
SNP call rate is a good indicator of genotype
probe performance. Removing SNPs with a greater
proportion of missing genotypes is essential to con-
trol for false positives, as spurious associations can
arise due to non-random missingness. Checking for
gross departure from Hardy–Weinberg equilibrium
(HWE) could help in identifying SNPs with geno-
typing errors (e.g. excess of heterozygotes).
Figure 1: Number of affected individuals required (given a case/control ratio of1:2) in order to achieve10, 50 and
90% power to detect an effect at  ¼5 10
 8 for variants with modest to low effect sizes (allelic odds ratios1.10,
1.15 and1.20) and varying risk allele frequencies: (a)0 . 0 5 ,( b)0 . 2 0 ,( c) 0.50 and (d) 0.90.Calculations assume complete
LD between the causal and genotyped variant.
Figure 2: Flowchart of the main quality control steps
in a GWA study.
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for SNPs with low-frequency alleles, it is current
practice in GWA studies to exclude rare SNPs
from single point analyses (these are underpowered
to detect effects anyway). Genotype calling algo-
rithms have the potential to make incorrect calls.
Therefore, inspecting intensity plots, though not
feasible on a genome-wide scale, is necessary for
SNPs with interesting association signals.
Sample call rate is a good indicator of hybridiza-
tion performance; high rates of missingness usually
indicate low DNA quality or problematic arrays.
Discrepancies in gender assignment (SNP data
versus phenotype data) can help identify sample
mix-ups. Excess genome-wide heterozygosity may
indicate possible contamination leading to a larger
proportion of heterozygous genotypes. Accidentally
duplicated and related individuals in large-scale stu-
dies can be identified through identity-by-descent
estimation given identity-by-state information in a
relatively large homogeneous sample [29]. Typically,
the sample with the lowest call rate from each pair of
related individuals is removed. Finally, ethnic outliers
can be detected and either removed or accounted for
in downstream analyses.
Population stratification can be a major con-
founding factor in GWA studies, both for case/
control designs and population-based quantitative
analyses. If undetected, it can lead to false positive
associations due to differences in allele frequency
between the different populations [30]. To guard
against it, most GWA scans attempt to match cases
and controls for broad ethnic background from
the outset and then rely on statistical approaches to
detect population substructure and correct for it
[29, 31, 32]. Genomic control ( ) is an estimate of
the degree of inflation of the test statistics genome-
wide and can serve as a crude correction factor [31].
Principal component analysis [32] and multidimen-
sional scaling [29] are methods employed to identify
individuals of different ethnic origin visualized
onto a two-dimensional projection on axes of
genetic variation. Inferred principal components
can be included as covariates in association analyses.
Directly typed SNPs in GWA studies are typically
analysed by single-point methods, most frequently
under the additive or multiplicative model. General
models are less frequently tested as they increase
dimensionality; dominant and recessive models are
equally parsimonious but generally less powerful
than the additive model. Multimarker tests (such as
sliding haplotype window analyses) are less feasible
at the genome-wide scale. However, imputation
approaches have recently been developed to take
into account information from multiple surrounding
markers in order to infer genotypes at untyped loci
[33]. Imputation therefore currently allows testing
for association at >2.5 million markers genome-
wide, thus maximizing information output from
GWA studies, and additionally serves as an ideal
tool for the combination of data from GWA scans
that have been carried out on different platforms.
The analysis of imputed data necessitates taking
into account uncertainty by analysing the full geno-
type probability distribution appropriately.
The sheer number of SNPs tested for association
with disease raises important statistical considera-
tions about type I error and statistical significance
levels. To account for the inflation in false positives,
a variety of approaches, such as the conservative
Bonferroni correction and the less stringent control
of the false discovery rate [34], have been proposed.
Obtaining empirical P-values after hundreds of
thousands or millions of permutations are an alterna-
tive but prohibitively computer-intensive way to
assess statistical significance. To overcome the mul-
tiple testing problem, stringent genome-wide signif-
icance thresholds have been proposed: adjustment
for 1–2 million independent tests at common
variants genome-wide has resulted in the aforemen-
tioned generally accepted significance threshold
of P¼5 10
 8 [22, 23]. In practise, most GWA
studies prioritize signals for follow-up on the basis
of their relative statistical strength for association
and on evidence accrued from bioinformatics
approaches. Replication in independent datasets
(of the same variant, in the same direction, under
the same model) constitutes the gold standard in
genetic association studies of any scale.
T2D serves as a prime example of the success
of the GWA scan approach. Over the past 2 years,
multiple GWA scans have been published, greatly
accelerating progress in identifying novel susceptibil-
ity variants for the disease [24, 35–42]. This first
wave of studies collectively raised the number of
established T2D loci to 11.
Approaches aiming to identify complex trait
susceptibility loci have recently also extended
to the meta-analysis of diverse scans carried out for
the same phenotype. This move in the field has been
brought about by the realization that effect sizes for
common variants are becoming increasingly low.
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important factors in boosting power for an associa-
tion study. Synergy across research groups, leading to
the synthesis of GWA scan results, can greatly
increase sample size and, hence, power to detect
small individual effects. Several design and analytical
challenges are associated with GWA scan meta-
analysis (reviewed in [43]). These collaborative
efforts have recently started to successfully extend
the list of robustly replicating associations with
complex traits [44–48]. For example, the Diabetes
Genetics Initiative, Finland–United States Investiga-
tion of NIDDM and Wellcome Trust Case Control
Consortium T2D scans undertook a three-way
meta-analysis, which led to the identification of 6
novel susceptibility loci [44].
FUTURE
The first wave of GWA studies and meta-analyses
conducted indicate that only a small amount of the
genetic variance underlying the heritable component
of common complex traits has been identified. For
example, in the case of T2D, the so far identified loci
account for <4% of the estimated heritability
(reviewed in [49]). This reflects the fact that current
studies involving thousands of individuals are still
underpowered to discover most of the common
genetic variants with the very modest to low effect
sizes that are likely to exist. It is anticipated that
sample sizes of many tens of thousands or even hun-
dreds of thousands will be required to fulfil this
purpose. The identification of further common
variants with small effect sizes may not have imme-
diate consequences in disease prediction and prog-
nosis, but will hopefully continue to provide novel
insights into implicated biological pathways, pointing
to new targets for therapy. Therefore, the future is
poised to continue in the same trend of large-scale
consortia being formed to facilitate the accumula-
tion of data and the combination of expertise, in
order to make the next generation of GWA scan
meta-analyses possible. These will in turn start to
enable the investigation of gene–gene and gene–
environment interactions, currently hindered by
low power.
The associated SNPs uncovered by GWA scans
are unlikely to be the functional polymorphisms.
One of the major challenges that the field of com-
plex disease genetics faces over the next few years
is how best to explore information in association
regions delineated by recombination hotspots,
typically spanning several kilobases, in order to iden-
tify the truly causal variants. Deep resequencing
in samples of interest and subsequent large-scale
follow-up of interesting markers through fine-
mapping is an emerging study design paradigm,
enabled by next generation sequencing technologies.
However, several study design issues remain unclear,
including the choice of resequencing and fine-
mapping samples and their ethnicity, sample size,
spectrum of typed marker allele frequency and
analytical approach. It is generally recognized that
the benefits of fine-mapping will be finite, particu-
larly in regions of very strong LD, and that functional
studies will be necessary in order to pinpoint the
truly causal variant. The availability of global gene
expression profiles coupled with genotype data
from the same samples can also serve as a valuable
resource, as associated variants might display strong
cis associations with expression of a nearby gene
whose expression levels are causally linked with the
underlying phenotype or disease trait [50].
The future of genetic association studies is poised
to have an increasing focus on CNVs; this will be
facilitated by ongoing efforts to provide a catalogue
of structural variants (e.g. the CNV project [51]).
Along with rare variants, CNVs could account for
some of the missing complex trait heritability.
For example, schizophrenia studies have uncovered
CNV associations [52, 53] in a disease where GWA
studies have not returned significant evidence for
robust common SNP associations (reviewed in [54]).
Current studies are focused on common variants,
which invariably have small effects. However, the
field is now starting to recognize the role of rare
variants, which can have larger effect sizes, in com-
plex disease susceptibility. The analysis of lower
frequency polymorphisms necessitates larger sample
sizes and tailored analytical approaches in order to
increase power [55]. The 1000 genomes project
[56] will improve our understanding of variation at
the lower end of the frequency spectrum and is
expected to enhance information capture and inter-
pretation in genetic association studies.
There is little doubt that large-scale sequencing
studies will constitute the way forward for character-
izing the allelic architecture of complex disease.
Several challenges with respect to the design, analysis
and interpretation of such studies continue to emerge
and will undoubtedly keep researchers busy for the
foreseeable future. The landscape of human complex
350 Panoutsopoulou and Zegginidisease genetics has witnessed major changes over the
past 10 years, and is poised to change even more
dramatically in the near future.
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  The genetic aetiology of complex traits is likely to be based on
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themajorityofcommon SNPs across thehumangenome.
  Sufficiently large sample sizes, stringent genotype QC, use of
appropriate significance thresholds and replication of findings
in independent datasets have been crucial determinants of
GWA study success.
  Further advancesingenotyping andnextgeneration sequencing
technologies, facilitating the study of rare and structural
variation, hold the promise of an improved understanding of
the allelic architecture of complexdisease.
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